Mineralys Therapeutics (Nasdaq: MLYS) announced inducement equity awards granted February 23, 2026 to a new non-executive employee under its 2025 Employment Inducement Incentive Award Plan.
The Compensation Committee granted a stock option for 27,920 shares and 20,940 restricted stock units. Options vest over four years starting February 23, 2026; RSUs vest 25% annually on each anniversary. Awards were made as an inducement per Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
Inducement stock options:27,920 sharesInducement RSUs:20,940 sharesOption vesting period:4 years+4 more
7 metrics
Inducement stock options27,920 sharesStock option award to one new non-executive employee
Inducement RSUs20,940 sharesRestricted stock unit award to one new non-executive employee
Option vesting period4 yearsInducement stock option vests over four-year period
Initial option vesting25%Portion of option vesting on first anniversary of Feb 23, 2026
Subsequent option vesting1/48th monthlyMonthly vesting after first anniversary, subject to service
RSU vesting schedule25% annually over 4 yearsRSUs vest 25% on each anniversary of Feb 23, 2026
Vesting commencement dateFebruary 23, 2026Vesting start date for both option and RSU awards
Market Reality Check
Price:$29.26Vol:Volume 781,732 is below 2...
normal vol
$29.26Last Close
VolumeVolume 781,732 is below 20-day average 1,086,254 (relative volume 0.72x).normal
TechnicalPrice $29.23 is trading above 200-day MA at $28.21, but 38.66% below 52-week high and 254.69% above 52-week low.
Peers on Argus
Among close biotech peers, moves were mixed: IMVT (-3.37%), VKTX (-0.96%), XENE ...
1 Down
Among close biotech peers, moves were mixed: IMVT (-3.37%), VKTX (-0.96%), XENE (-0.94%), CRNX (-2.14%) declined while SLNO rose 4.72%. Only XENE appeared in momentum scans, suggesting today’s action in MLYS is more stock-specific than sector-driven.
Common CatalystSame-day peer news includes XENE earnings and SLNO management change, pointing to routine company-specific catalysts rather than a unified sector event.
Q3 2025 financials with large cash balance and equity raise, plus pipeline updates.
Pattern Detected
Recent news skewed positive or neutral, with mostly aligned positive price reactions; prior inducement grants have sometimes coincided with modest to sharp declines.
Recent Company History
Over the last few months, Mineralys combined routine equity grant updates with major clinical and corporate milestones. A Nov 2025 earnings update highlighted strong cash of $593.6M and financing of $287.5M, while JAMA recognition in Dec 2025 underscored positive Phase 3 Launch-HTN data. An NDA for lorundrostat followed multiple successful trials, and several inducement awards in Nov 2025 and Feb 2026 provided equity incentives to new hires. Today’s inducement award fits this pattern of ongoing equity-based compensation alongside a progressing clinical program.
Market Pulse Summary
This announcement details standard inducement equity awards to a new non-executive employee, includi...
Analysis
This announcement details standard inducement equity awards to a new non-executive employee, including 27,920 stock options and 20,940 RSUs vesting over four years under the 2025 Employment Inducement Incentive Award Plan. It follows a series of similar grants and board-level equity awards reported in recent Form 4 filings. In context of earlier NDA progress and JAMA-recognized Phase 3 data, investors may monitor the cumulative impact of ongoing equity issuance and future clinical or regulatory milestones.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +4 more
8 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"and other diseases driven by dysregulated aldosterone, announced today that on"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
stock optionfinancial
"granted an inducement stock option award covering 27,920 shares and an inducement"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
restricted stock unitfinancial
"and an inducement restricted stock unit award covering 20,940 shares of Mineralys"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material to the new non-executive employee... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
AI-generated analysis. Not financial advice.
RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to one new non-executive employee.
The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of each award’s vesting commencement date, February 23, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock units will vest over a four-year period, with 25% of the shares vesting on each of the four anniversaries of each award’s vesting commencement date, February 23, 2026. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
FAQ
What inducement awards did Mineralys (MLYS) grant on February 23, 2026?
Mineralys granted a stock option for 27,920 shares and 20,940 restricted stock units. According to the company, these awards were issued under the 2025 Employment Inducement Incentive Award Plan as an inducement for a new non-executive hire.
How do the Mineralys (MLYS) option vesting terms work for the February 23, 2026 grant?
The option vests over four years with 25% vesting on the first anniversary and then 1/48th monthly thereafter. According to the company, vesting is subject to continued service from February 23, 2026.
What is the vesting schedule for the restricted stock units Mineralys (MLYS) granted?
The RSUs vest over four years with 25% of shares vesting on each anniversary starting February 23, 2026. According to the company, vesting is annual and conditioned on continued service through each anniversary date.
Under which plan and Nasdaq rule were the Mineralys (MLYS) inducement awards granted?
The awards were granted under the 2025 Employment Inducement Incentive Award Plan and made in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, the awards were material inducements for hiring the new employee.
Will the February 23, 2026 Mineralys (MLYS) awards likely dilute existing shareholders immediately?
The awards create potential future dilution if shares vest and are issued, but they do not immediately issue shares. According to the company, the awards are standard inducement equity subject to vesting and continued service.
